Simmitinib

Primary objectives: 1. To quantitatively analyze the total radioactivity in excreta after oral administration of [14C] HA1818 to healthy male participants, and to obtain the human radioactivity recovery rate and main excretion pathway; 2. To investigate the distribution ratio of total radioactivity in whole blood and plasma after oral administration of [14C] HA1818 to healthy male participants, as well as the pharmacokinetic characteristics of total radioactivity in whole blood (if applicable) and plasma; 3. To obtain the radioactive metabolite profiles in plasma, urine and feces of healthy male participants after oral administration of [14C] HA1818, identify the main metabolites, and determine the main biotransformation pathways. Secondary objectives: 1. To quantitatively analyze the concentrations of HA1818 and its main metabolites (if applicable) in plasma using a validated LC-MS/MS method, and to obtain the pharmacokinetic parameters of HA1818 and its main metabolites (if applicable) in plasma; to observe the safety of Chinese healthy adult male participants after a single oral administration of [14C] HA1818.